SCHEMBL6747772

SCHEMBL6747772

CCOC(=O)Cc1cc(=O)c2ccccc2o1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.59
LMNA P02545 2/20 0.59
HPGD P15428 2/20 0.59
HSD17B10 Q99714 1/20 0.59
TNKS O95271 3/20 0.58
MAPT P10636 2/20 0.53
MEN1 O00255 1/20 0.53
GALR3 O60755 1/20 0.53
KMT2A Q03164 1/20 0.53
MAOB P27338 2/20 0.53
PPARG P37231 1/20 0.50
CSNK2A2 P19784 2/20 0.48
CSNK2B P67870 2/20 0.48
CSNK2A1 P68400 2/20 0.48
ALDH1A1 P00352 2/20 0.48
RAB9A P51151 2/20 0.47
NPC1 O15118 1/20 0.47
CASP3 P42574 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31217586 0.86 KDM4E (0.54) KDM4ELMNAHPGDHSD17B10TNKS
SCHEMBL5947962 0.81 MAOB (0.52) KDM4EHPGDHSD17B10MAPTMEN1
SCHEMBL27664301 0.81 PPARG (0.56) KDM4ELMNAHPGDHSD17B10TNKS
SCHEMBL312117 0.80 TNKS (0.55) KDM4ELMNAHPGDHSD17B10TNKS
SCHEMBL7044128 0.79 PPARG (0.62) KDM4ELMNAHPGDTNKSMAPT
SCHEMBL10215485 0.79 HPGD (0.59) KDM4ELMNAHPGDHSD17B10TNKS
SCHEMBL312120 0.78 TNKS (0.53) KDM4ELMNAHPGDHSD17B10TNKS
SCHEMBL30285083 0.77 MAOB (0.80) KDM4ELMNAHPGDHSD17B10TNKS
SCHEMBL3359780 0.77 MAOB (0.80) KDM4ELMNAHPGDHSD17B10TNKS
SCHEMBL9972758 0.77 PPARG (0.63) KDM4ELMNAHPGDHSD17B10TNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6756403-B2 6-AMINOCHROMAN-2-YL CARBOXYLIC ACIDS AND ESTERS AS PLATELET AGGREGATION INHIBITORS; FROM PHENOL AND KETOGLUTARIC ACID; OR FROM 2-HYDROXYACETOPHENONE AND DIETHYLOXALATE; OR FROM NITROPHENOL AND DIETHYL ESTER OF MALEIC ACID ELI LILLY AND COMPANY 2004-06-29 US disclosed
US-20040053992-A1 Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor ELI LILLY AND COMPANY 2004-03-18 US disclosed
EP-1292589-A2 METHODS FOR PRODUCING CHIRAL CHROMONES, CHROMANES, AMINO SUBSTITUTED CHROMANES AND INTERMEDIATES THEREFOR MILLENIUM PHARMACEUTICALS, INC. (US) 2003-03-19 EP disclosed
WO-2001094335-A2 METHODS FOR PRODUCING CHIRAL CHROMONES, CHROMANES, AMINO SUBSTITUTED CHROMANES AND INTERMEDIATES THEREFOR ELI LILLY & COMPANY (US) 2001-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053992-A1 Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor NOTUM, FAR1, CYP51A1 KDM4E 3216/4885LMNA 3637/4885HPGD 666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.